These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9762359)

  • 61. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer.
    Koukourakis MI; Giatromanolaki A; Sivridis E; Pastorek J; Karapantzos I; Gatter KC; Harris AL;
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):67-71. PubMed ID: 15093900
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibody-directed targeting of the vasculature of solid tumors.
    Thorpe PE; Burrows FJ
    Breast Cancer Res Treat; 1995; 36(2):237-51. PubMed ID: 8534871
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
    Horsman MR; Siemann DW
    Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
    Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
    J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.
    Fabian KL; Storkus WJ
    Adv Exp Med Biol; 2017; 1036():191-211. PubMed ID: 29275473
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mechanisms and future directions for angiogenesis-based cancer therapies.
    Scappaticci FA
    J Clin Oncol; 2002 Sep; 20(18):3906-27. PubMed ID: 12228212
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vascular endothelial growth factor and vascular targeting of solid tumors.
    Brekken RA; Thorpe PE
    Anticancer Res; 2001; 21(6B):4221-9. PubMed ID: 11908675
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.
    Burrows FJ; Watanabe Y; Thorpe PE
    Cancer Res; 1992 Nov; 52(21):5954-62. PubMed ID: 1394221
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
    Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
    Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
    Fenton BM; Paoni SF
    Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition.
    Gee MS; Makonnen S; al-Kofahi K; Roysam B; Payvandi F; Man HW; Muller GW; Lee WM
    Cancer Res; 2003 Dec; 63(23):8073-8. PubMed ID: 14678955
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cycling hypoxia: A key feature of the tumor microenvironment.
    Michiels C; Tellier C; Feron O
    Biochim Biophys Acta; 2016 Aug; 1866(1):76-86. PubMed ID: 27343712
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tumor microenvironmental physiology and its implications for radiation oncology.
    Vaupel P
    Semin Radiat Oncol; 2004 Jul; 14(3):198-206. PubMed ID: 15254862
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
    Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
    Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status.
    Evans SM; Jenkins WT; Shapiro M; Koch CJ
    Adv Exp Med Biol; 1997; 411():215-25. PubMed ID: 9269430
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy.
    Gee MS; Procopio WN; Makonnen S; Feldman MD; Yeilding NM; Lee WM
    Am J Pathol; 2003 Jan; 162(1):183-93. PubMed ID: 12507901
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Platelet-Mimicking Biotaxis Targeting Vasculature-Disrupted Tumors for Cascade Amplification of Hypoxia-Sensitive Therapy.
    Zhang M; Ye JJ; Xia Y; Wang ZY; Li CX; Wang XS; Yu W; Song W; Feng J; Zhang XZ
    ACS Nano; 2019 Dec; 13(12):14230-14240. PubMed ID: 31714733
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Vascular and interstitial barriers to delivery of therapeutic agents in tumors.
    Jain RK
    Cancer Metastasis Rev; 1990 Nov; 9(3):253-66. PubMed ID: 2292138
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Role of Regular Physical Exercise in Tumor Vasculature: Favorable Modulator of Tumor Milieu.
    Esteves M; Monteiro MP; Duarte JA
    Int J Sports Med; 2021 May; 42(5):389-406. PubMed ID: 33307553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.